Logo

Argenx Reports EMA's Validation of MAA for Efgartigimod to Treat Generalized Myasthenia Gravis

Share this

Argenx Reports EMA's Validation of MAA for Efgartigimod to Treat Generalized Myasthenia Gravis

Shots:

  • The MAA is based on the P-III ADAPT trial evaluating the safety and efficacy of efgartigimod vs PBO in a ratio (1:1) in 167 adult patients with gMG for 26wks.
  • The 1EPs was the proportion of AChR-Ab+ patients who achieved a response on the MG-ADL score defined by at least a two-point improvement for ≥4wks. consecutively
  • If approved- the therapy will be the 1st approved FcRn antagonist in the EU & is currently under FDA’s review for gMG with an anticipated PDUFA date as Dec 17- 2021. Additionally- the company has submitted the application to PMDA in early 2021

Click hereRef: GlobeNewswire | Image: Cowen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions